Lord's Mark Industries Limited, one of India's fastest-growing diversified business groups, has announced the successful completion and dispatch of its first MedTech order for USD 1 million to the United States of America. The milestone solidifies the company's global expansion and strengthens India's expanding presence in innovative healthcare technology exports.

Key Highlights

• Lord’s Mark completes first USD 1 million MedTech shipment to the USA. 
• Includes AI-based Early Warning Systems and Contactless Remote Patient Monitoring made in India.

The shipment includes Contactless Remote Patient Monitoring (RPM) and AI-based Early Warning Systems (EWS), next-generation healthcare solutions designed, developed, and manufactured wholly in India. These systems use real-time patient monitoring, predictive analytics, and EHR integration to provide proactive, data-driven clinical care.

"This milestone reinforces India's position as a hub for high-quality MedTech innovation," said Sachidanand Upadhyay, Managing Director of Lord's Mark Industries Ltd. "Our maiden cargo to the United States is more than just an export; it demonstrates India's growing global MedTech leadership. We are developing world-class healthcare technology that fulfill the most stringent criteria, establishing Lord's Mark Industries Ltd. as a global force and Indian innovation as a reliable benchmark in international markets."

Also Read: Trump's 500% Tariff Threat Puts India's Oil Imports at Risk

LordsMark Industries Ltd. works through significant subsidiaries such as LordsMed, LordsMark Biotech Pvt Ltd., and LordsMark Microbiotech Pvt Ltd. Committed to innovation and excellence, the organization continues to grow while adhering to the highest quality standards. Diversification remains the cornerstone of Lord's Mark Industries' continued growth and success.

Lord's Mark Industries Ltd. (Lord's), founded in 1998, has emerged as a powerful player in the healthcare and diagnostics industries. Building on a rich history of innovation, the company has deliberately expanded into medical diagnostics, pharmaceuticals, and genetic testing, establishing a strong position throughout the healthcare value chain.